StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)

Fri, 16 Oct 2026 06:49:47 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $152.00 price target on Incyte (NASDAQ: INCY).

The analyst commented: "Verastem’s chemo-free disease control supports the rationale for continuing Incyte’s ’734 after chemo reduction. On October 14, Verastem (VSTM; Maldonado; Buy) reported 67% six-month PFS and nine confirmed responses among 22 previously treated KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC) patients receiving VS-7375 900 mg daily as monotherapy, representing a 41% confirmed ORR at 6.4 months median follow-up. Patients had received a median of two prior treatment lines. Like VS-7375, Incyte’s INCB161734 (’734) selectively inhibits both ON- and OFF-state KRAS G12D.

Form 144 INCYTE CORP Filed by: CAGNONI PABLO J

Thu, 15 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261015/27193267.html

Incyte (INCY) PT Raised to $115 at Truist Securities

Wed, 14 Oct 2026 07:00:04 -0400

Truist Securities analyst Srikripa Devarakonda raised the price target on Incyte (NASDAQ: INCY) to $115.00 (from $105.00) while maintaining a Hold rating.

H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)

Tue, 13 Oct 2026 06:46:58 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $152.00 price target on Incyte (NASDAQ: INCY).

The analyst commented: "Newly released FDA documents reveal meaningful G12D response gap, strengthening case for Incyte's '734 ahead of ESMO. On October 8, FDA released its detailed regulatory review supporting the August approval of Revolution Medicines' Rasonque (daraxonrasib). Our review uncovered a notable difference beneath the pooled RASolute 302 results: confirmed response was 24% in KRAS G12D pancreatic ductal adenocarcinoma (PDAC; 23/95 patients) vs. 50% in G12V (47/94), despite comparable PFS benefit (HR 0.48 vs. 0.54). G12D accounts for ~40% of PDAC and represents

Incyte to Report Third Quarter Financial Results

Thu, 08 Oct 2026 08:00:00 -0400

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Thursday, October 29, 2026.

The schedule for the press release and conference call/webcast is as follows:

Q3 2026 Press Release: October 29, 2026, at 7:00 a.m. ET
Q3 2026 Conference Call: October 29, 2026, at 8:00 a.m. ET
Domestic Dial-In Number: 877-407-3042
International Dial-In Number: 201-389-0864
Conference ID Number: 13763051

If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the

Incyte to Report Third Quarter Financial Results

Thu, 08 Oct 2026 08:00:00 -0400

The schedule for the press release and conference call/webcast is as follows:

Q3 2026 Press Release: October 29, 2026, at 7:00 a.m. ET
Q3 2026 Conference Call: October 29, 2026, at 8:00 a.m. ET
Domestic Dial-In Number: 877-407-3042
International Dial-In Number: 201-389-0864
Conference ID Number: 13763051

If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

Tue, 06 Oct 2026 07:35:00 -0400

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

Tue, 06 Oct 2026 07:35:00 -0400

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

Tue, 06 Oct 2026 07:35:00 -0400

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

Tue, 06 Oct 2026 07:35:00 -0400

“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class

Form 4 INCYTE CORP For: Oct 01 Filed by: Heeson Lee

Mon, 05 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261005/27148610.html

Incyte (INCY) PT Raised to $127 at UBS, Neutral Rating Maintained

Mon, 05 Oct 2026 09:29:32 -0400

UBS analyst Ashwani Verma raised the price target on Incyte (NASDAQ: INCY) to $127.00 (from $113.00) while maintaining a Neutral rating.

The analyst commented, "Heading into YE, the key focus is on the G12D data expected at ESMO & the mCALR 1L MF update at ASH. Our recent KOL checks in the PDAC space increase our confidence in the G12D opportunity. For '734, INCY will share Ph1 data in both 1L PDAC (combining '734 with GeMNabP, mFOLFIRINOX) and 2L+ CRC (monotherapy and cetuximab combo) cohorts. However, heading into ESMO we believe a lot of the core facts are already known and we do not

Incyte (INCY) PT Raised to $127 at UBS, Neutral Rating Maintained

Mon, 05 Oct 2026 09:29:32 -0400

UBS analyst Ashwani Verma raised the price target on Incyte (NASDAQ: INCY) to $127.00 (from $113.00) while maintaining a Neutral rating.

Incyte (INCY) PT Raised to $157 at Stifel

Mon, 05 Oct 2026 05:28:19 -0400

Stifel analyst Stephen Willey raised the price target on Incyte (NASDAQ: INCY) to $157.00 (from $145.00) while maintaining a Buy rating.

The analyst comments "We recently hosted a series of investor meetings with Bill Meury (CEO) and Alexis Smith (VP/IR) ahead of multiple YE26 data catalysts anticipated from the late-stage pipeline at both ESMO (G12Di, PD-1xTGFBR2) and ASH (mCALR). Management’s disclosure framework for these events keeps us constructive over the near-term and we believe INCY’s competitive positioning with a mostly first-in-class pipeline in high-value GI oncology (1L PDAC/mCRC) and hematology indications remains underappreciated here. And while Jakafi LOE (YE28) appropriately dominates

Incyte (INCY) PT Raised to $157 at Stifel

Mon, 05 Oct 2026 05:28:19 -0400

Stifel analyst Stephen Willey raised the price target on Incyte (NASDAQ: INCY) to $157.00 (from $145.00) while maintaining a Buy rating.

Form 4 INCYTE CORP For: Sep 30 Filed by: Baker Brothers Life Sciences LP

Fri, 02 Oct 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20261002/27143785.html

Form 4 INCYTE CORP For: Sep 30 Filed by: Clancy Paul J

Fri, 02 Oct 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20261002/27142022.html

Form 4 INCYTE CORP For: Sep 30 Filed by: HARRIGAN EDMUND

Fri, 02 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261002/27142006.html

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

Mon, 28 Sep 2026 09:03:00 -0400

NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secretary.

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

Mon, 28 Sep 2026 09:03:00 -0400

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

Mon, 28 Sep 2026 09:03:00 -0400

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

Mon, 28 Sep 2026 09:03:00 -0400

Incyte (INCY) PT Raised to $123 at JPMorgan

Mon, 28 Sep 2026 08:38:24 -0400

JPMorgan analyst Jessica Fye raised the price target on Incyte (NASDAQ: INCY) to $123.00 (from $120.00) while maintaining a Neutral rating.

Incyte (INCY) PT Raised to $152 at H.C. Wainwright

Mon, 28 Sep 2026 06:57:03 -0400

(Updated - September 28, 2026 6:57 AM EDT)

H.C. Wainwright analyst Mitchell Kapoor raised the price target on Incyte (NASDAQ: INCY) to $152.00 (from $150.00) while maintaining a Buy rating.

The analyst commented: "Atebrioz approval unlocks roughly $205–225M of near-term gross economics before milestones and royalties. The FDA approved Atebrioz (zilurgisertib) 100mg once-daily to reduce total new heterotopic ossification (HO) volume in fibrodysplasia ossificans progressiva (FOP) patients aged ≥12, with U.S. availability expected in October. Approval triggers a $25M payment to Incyte and the FDA issued the Rare Pediatric Disease Priority Review Voucher (PRV) directly to Incyte; in addition, Incyte also retains

Incyte (INCY) PT Raised to $152 at H.C. Wainwright

Mon, 28 Sep 2026 06:57:03 -0400

(Updated - September 28, 2026 6:57 AM EDT)

H.C. Wainwright analyst Mitchell Kapoor raised the price target on Incyte (NASDAQ: INCY) to $152.00 (from $150.00) while maintaining a Buy rating.